Summary
The role of an immune response in recombinant-human-tumor-necrosis-factor(rHTNF)-mediated regression of a weakly immunogenic, MCA-106 sarcoma in vivo was examined. C57BL/6 mice bearing established 10-day s.c. tumor were treated with single i.v. doses (8 μg) of rHTNF. rHTNF administration resulted in marked hemorrhagic necrosis and subsequent regression of tumor in treated mice. Mice cured of MCA-106 sarcoma by rHTNF specifically rejected a subsequent challenge (5×105 cells) of the same tumor (P<0.01) but not of the antigenically distinct, syngeneic MCA-105 sarcoma. Tumor bearers were depleted in vivo of selective T-cell subsets by the systemic administration of specific monoclonal antibodies before rHTNF therapy. rHTNF-induced regression, but not hemorrhagic necrosis of the MCA-106 sarcoma was blocked in mice depleted of Lyt-2+ cells, but not of L3T4+ cells. The in vivo role of T-cell subsets in rHTNF-mediated tumor regression is discussed.
This is a preview of subscription content, log in via an institution to check access.
References
Asher AL, Mulé JJ, Reichert CM, Shiloni E, Rosenberg SA (1987) Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138:963–974
Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Willamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72:3666–3670
Cobbold SP, Jayasuriya A, Nash A, Prospero TD, Waldmann H (1986) Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 323:164–168
Cobbold SP, Martin G, Qin S, Waldmann H (1986) Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature 323:164–167
Greenberg PD, Kern DE, Jensen M, Klanet JP, Cheever MA (1987) Effector mechanisms by which adoptively transferred T cells promote tumor eradication. In: Cellular immunotherapy of cancer. Truitt RL, Gale RP, Bortin MM (eds) Alan R. Liss Inc., New York, pp 127–135
Haranaka K, Satomi N (1981) Cytotoxic activity of tumor necrosis factor (TNF) on human cancer cells in vitro. Jpn J Exp Med 51:191–194
Haranaka K, Satomi N, Sakurai A (1984) Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer 34:263–267
Helson L, Green S, Carswell E, Old LO (1975) Effect of tumor necrosis factor on cultured human melanoma cells. Nature 258:731–734
Helson L, Helson C, Green S (1979) Effects of murine tumor necrosis factor on heterotransplanted human tumors. Exp Cell Biol 47:53–60
Hori K, Ehrke MJ, Mace K, Maccubin D, Doyle MJ, Otsuka Y, Mihich E (1987) Effect of recombinant human tumor necrosis factor on the induction of murine macrophage tumoricidal activity. Cancer Res 47:2793–2798
Mulé JJ, Yang JC, Lafreniere R, Shu S, Rosenberg SA (1987) Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2. J Immunol 139:285–294
Philip R, Epstein L (1986) Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, γ-interferon and interleukin-1. Nature 323:86–89
Ranges GE, Figari IS, Espevik T, Palladino MA (1987) Inhibition of cytotoxic T cell development by transforming growth factor B and reversal by recombinant tumor necrosis factor-α. J Exp Med 166:991–996
Ruff MR, Giford GE (1980) Purification and physicochemical characterization of rabbit tumor necrosis factor. J Immunol 125:1671–1678
Scheurich P, Thoma B, Ucer V, et al. (1987) Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-α: induction of TNF receptors on human T cells and TNF-α mediated enhancement of T cell responses. J Immunol 138:1786–1790
Shalaby MR, Aggarwal BB, Rinderknecht E, et al. (1985) Activation of human polymorphonuclear neutrophil functions by interferon-γ and tumor necrosis factors. J Immunol 135:2069–2073
Shu S, Rosenberg SA (1985) Adoptive immunotherapy of a newly induced sarcoma: Immunologic characteristics of effector cells. J Immunol 135:2895–2902
Shu S, Rosenberg SA (1985) Adoptive immunotherapy of newly induced murine sarcomas. Cancer Res 45:1657–1664
Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA, Shepard HM (1985) Recombinant human tumor necrosis factor-α: effects on proliferation of normal and transformed cells in vitro. Science 230:943–945
Weber JS, Jay G, Tanaka K, Rosenberg SA (1987) Immunotherapy of a murine tumor with interleukin-2: increased sensitivity after MHC class I gene transfection. J Exp Med 166:1716–1733
Wexler H, Rosenberg SA (1966) Accurate identification of experimental pulmonary metastases. JNCI 36:641–643
Williamson BD, Carswell EA, Rubin BY, Prendergast JS, Old LO (1983) Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci USA 80:5397–5401
Zucali JR, Elfenbein GJ, Barth KC, Di Narello CA (1987) Effects of human interleukin-1 and tumor necrosis factor on human T lymphocyte colony formation. J Clin Invest 80:772–777
Author information
Authors and Affiliations
Additional information
Howard Hughes Medical Institute Research Scholar
Rights and permissions
About this article
Cite this article
Asher, A.L., Mulé, J.J. & Rosenberg, S.A. Recombinant human tumor necrosis factor mediates regression of a murine sarcoma in vivo via Lyt-2+ cells. Cancer Immunol Immunother 28, 153–156 (1989). https://doi.org/10.1007/BF00199117
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00199117